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MION = superparamagnetic monocrystalline ironoxide nanoparticle; MR = magnetic resonance; Tf = transferrin; TfR = transferrin receptor.
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Introduction
Breast cancer is one of the most frequently diagnosed
malignancies and the second leading cause of cancer
deaths in American females [1]. Several improvements in
diagnostic protocols have enhanced our ability for earlier
detection of breast cancer, resulting in improvement of
therapeutic outcome and an increased survival rate for
breast cancer victims [2–4]. The importance of early detec-
tion of breast tumors therefore cannot be overemphasized.
Current early screening techniques are, however, neither
comprehensive nor infallible, especially in women with
radiographically dense breasts. Recent data from the
Edinburgh randomized trial of breast screening as well as
other retrospective analyses of ‘false-negative’ mammo-
grams demonstrate that approximately one-third of diag-
nosed cancers were visible on early ‘negative’
mammograms [2,5,6]. Early detection of breast cancer
therefore still presents a significant diagnostic challenge.
Imaging techniques that improve breast cancer detection,
localization, and evaluation of therapy would be a major
breakthrough in combating the disease.
Detection of malignant tumor cells in a background of
normal or hyperplastic benign tissue is often based on dif-
ferences in physical properties between tissues, which are
frequently minimal (eg proton relaxation times, X-ray
absorption, ultrasound scattering), resulting in low con-
trast resolution; that is, small tumors are not detectable.
To enhance detection of small tumors, several groups
have been developing the concept of molecular imaging
as a way to increase the signal to noise ratio by detecting
the differences in ‘molecular properties’ between cancer
and normal tissues that arise as a result of malignant
transformation. This should, in theory, allow for earlier
detection of smaller tumors.
The following reviews in this series will describe how
state-of-the-art imaging modalities (magnetic resonance
[MR] imaging, magnetic resonance spectroscopy, nuclear
imaging, and optical imaging) are being used to more pre-
cisely identify human breast tumors and monitor
chemotherapeutic response. Not all of the cited technolo-
gies are yet able to take advantage of the underlying mole-
cular properties resulting in altered tumor biology;
however, many have been developed to the point of being
able to exploit macromolecular changes in tumor physiol-
ogy and/or metabolism to increase detection of diseased
tissue. Part of the problem in exploiting the underlying mol-
ecular changes manifest as altered physiology or metabo-
lism is the lack of genetic information. As advances in
gene profiling allow dissection of underlying molecular
profiles of tumors, imaging approaches will be more mole-
cularly based. Uncovering and understanding the molecu-
lar aberrations directly underlying the measurable
biological differences, as examples from our own work
demonstrate (see below), will allow molecular refinement
of the imaging tools and, presumably, more sensitive
tumor detection.
Molecular imaging of cancer
Molecular imaging, defined as the in vivo characterization
and measurement of biological processes at the cellular
and molecular level, is an attempt to image the molecular
Review
Current and future technologies for breast cancer imaging
James P Basilion
Center for Molecular Imaging Research, NFCR Center for Molecular Analysis and Imaging, Massachusetts General Hospital–Harvard Medical School,
Charlestown, Massachusetts, USA
Correspondence: James P Basilion, Assistant Professor, Center for Molecular Imaging Research, NFCR Center for Molecular Analysis and Imaging,
Massachusetts General Hospital–Harvard Medical School, Building 149, 13th Street #5406, Charlestown, MA 02129, USA. 
E-mail: basilion@helix.mgh.harvard.edu
Received: 17 November 2000
Accepted: 27 November 2000
Published: 13 December 2000
Breast Cancer Res 2001, 3:14–16
© Biomed Central Ltd on behalf of the copyright holder
(Print ISSN 1465-5411; Online ISSN 1465-542X)Available online http://breast-cancer-research.com/content/3/1/014
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
make-up of the macrofeatures currently visualized using
‘classical’ diagnostic imaging modalities. Differences in
molecular properties of cells may result from genetic
manipulation via gene transfer vectors or, as is the case for
cancer, are manifest as a result of inappropriate expression
of specific gene products in the diseased tissue. While the
expression levels of many genes may be altered in cancer,
there are few examples where an overexpressed gene is
detectable in the cancer tissue but not in normal tissue. To
exploit differences in the genetic make-up of normal and
malignant tissues, it is therefore necessary to develop an
imaging strategy that detects relative differences in gene
expression between these tissues.
The molecular imaging approach we have been develop-
ing is based on the discovery that several cell-surface
internalizing receptors are overexpressed on cancer cells
relative to surrounding tissues [7]. Several studies of dif-
ferent cancers, including cancers of the breast, have cor-
related expression of the transferrin receptor (TfR) to
tumor grade and metastatic potential, and it has been sug-
gested that receptor levels may be helpful in grading
tumors and determining prognosis [8–10]. The transferrin
receptor is a cell-surface internalizing receptor responsible
for almost all iron sequestration in mammalian cells. Over-
expression of the TfR on cancer cells is presumably sec-
ondary to increased cellular metabolism, for which iron is
required. We are attempting to enhance detection of
tumor tissues by trying to directly image this altered mol-
ecular property of cancers using MRI.
We have hypothesized that conjugating ligands for the TfR
to a MR contrast agent (superparamagnetic monocrys-
talline ironoxide nanoparticles [MIONs]) would selectively
increase uptake of MIONs into cells overexpressing the
receptor, resulting in an altered MR signal. This hypothesis
has been tested using the TfR and holo transferrin-MION
(Tf-MION) conjugates. Both other workers and ourselves
have shown that as little as a fivefold [11–13] overexpres-
sion of the TfR on tumor cells can be detected using Tf-
MION, which results in a 400-fold increase in MR imaging
sensitivity in vivo (Fig. 1). Detection of a modest fivefold
increase in the TfR receptor depends on several synergis-
tic factors characteristic of the receptor system (detailed
in [13]). These characteristics are shared by several other
receptors, suggesting that this concept for increasing MR
imaging sensitivity could be extended to other receptor
systems and is applicable to a large number of cancers,
including breast cancer. Application of molecular imaging
to breast cancer imaging has the potential to radically
improve breast cancer detection, localization, and evalua-
tion of therapy, and would be a major breakthrough in
combating the disease.
Studies aimed at determining the level of overexpression
of the transferrin and other internalizing cell surface recep-
tors on human breast cancers are currently underway in
our laboratory. The statistically significant database of
receptor targets on breast cancers that will be created by
these studies will enable probe development to allow
molecular imaging based on tumor-selective markers.
Figure 1
In vivo MR imaging. MR image of a single mouse with TfR+ and TfR– flank tumors. (a) The T1-weighted coronal SE image (imaging time, 3.5 min; 300
× 300 × 3000 mm3 voxel resolution). TfR– tumors (right arrowhead) and TfR+ tumors (left arrowhead) have similar signal intensity. (b) Corresponding
T2-weighted gradient echo image showing significant difference between TfR– and TfR+ tumors (imaging time, 8 min; 300 × 300 × 3000 mm3 voxel
resolution). TfR-mediated cellular accumulation of the superparamagnetic probe decreases signal intensity as expected. These differences in MR signal
intensity were most pronounced using T2- and T2*-weighted imaging pulse sequences consistent with the increased R2 upon cellular internalization. 
(c) Composite of a T1-weighted spin echo image obtained for anatomic detail with superimposed R2 changes after Tf-MION administration displayed
in a color map. Note the difference in R2 changes between the TfR+ and TfR– tumors (asterisks). Scale bar, 10 mm; N = 1. (Reproduced with permission
from Weissleder et al [13].)
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Demonstrating the feasibility of enhanced MR imaging of
cancer due to overexpression of cell surface receptors
can, in theory, be applied to other biological systems. For
example, targeted MR imaging agents might be useful to
enhance MR imaging of tumor vascularization. It is clear in
Dr Leach’s review on MR imaging of angiogenesis that dif-
ferences in dynamic contrast measurements can aid in
discerning normal or benign from neoplastic breast
tissues. The molecular basis for these detectable differ-
ences may be explained, in part, by the findings of Croix et
al showing that dramatic differences in endothelial cell
gene expression (20-fold and greater) exist between
endothelial cells derived from tumor and nontumor related
vasculature [14]. Development of imaging agents that
would target these relative differences in gene expression
could significantly enhance the sensitivity of MR imaging
to detect malignancy-related angiogenesis. This approach
is, of course, not limited to MR techniques or angiogene-
sis imaging. Similarly, identification of cancer-related gene
products (eg enzymes) whose overexpression in tumors
themselves or tumor vasculature could be exploited to
activate MR, optical, or nuclear imaging probes (see
[15,16]) would be a significant addition to the cutting
edge technologies described in the subsequent reviews.
Only now is the potential of molecular imaging being fully
recognized. The progression of imaging sciences and mol-
ecular analysis of the human organism have traveled on
parallel paths — only recently to intersect and inform
insightful developments for molecular imaging. In the fol-
lowing sections, the authors review the current state of
several imaging modalities as they apply to breast cancer
and will highlight where interdisciplinary nodes occur by
referring to or describing studies that are beginning to
exploit these intersections to develop novel molecular
imaging strategies.
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